CN115551860A - 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物 - Google Patents

作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物 Download PDF

Info

Publication number
CN115551860A
CN115551860A CN202180034352.7A CN202180034352A CN115551860A CN 115551860 A CN115551860 A CN 115551860A CN 202180034352 A CN202180034352 A CN 202180034352A CN 115551860 A CN115551860 A CN 115551860A
Authority
CN
China
Prior art keywords
halogen
nrr
substituted
group
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180034352.7A
Other languages
English (en)
Inventor
赵焰平
刘彬
姜媛媛
仲伟婷
徐慧芬
王红军
冒莉
李敬涛
张宏雷
黄闯闯
李晶
赵静
刘伟娜
田娜娜
周丽莹
刘亚男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Tide Pharmaceutical Co Ltd
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Publication of CN115551860A publication Critical patent/CN115551860A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

提供通式(I)化合物，它们可用于治疗ATR激酶介导的疾病，例如增生性疾病，例如癌症。还提供通式(I)化合物的药物组合物、其用于治疗ATR激酶介导的疾病的用途、及其制备。

Description

PCT国内申请，说明书已公开。

Claims (29)

  1. PCT国内申请，权利要求书已公开。
CN202180034352.7A 2020-05-20 2021-05-20 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物 Pending CN115551860A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010429678 2020-05-20
CN2020104296787 2020-05-20
CN2021104180268 2021-04-19
CN202110418026 2021-04-19
PCT/CN2021/094871 WO2021233376A1 (zh) 2020-05-20 2021-05-20 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物

Publications (1)

Publication Number Publication Date
CN115551860A true CN115551860A (zh) 2022-12-30

Family

ID=78708100

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180034352.7A Pending CN115551860A (zh) 2020-05-20 2021-05-20 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物

Country Status (6)

Country Link
US (1) US20230212160A1 (zh)
EP (1) EP4155307A4 (zh)
JP (1) JP2023528289A (zh)
KR (1) KR20230012584A (zh)
CN (1) CN115551860A (zh)
WO (1) WO2021233376A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7485701B2 (ja) * 2019-06-06 2024-05-16 北京泰徳製薬股▲フン▼有限公司 Ａｔｒキナーゼ阻害剤としての２，４，６－三置換ピリミジン化合物

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008032086A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab 2-benzimidazolyl-6-morpholino-4-phenylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2009093981A1 (en) * 2008-01-23 2009-07-30 S Bio Pte Ltd Triazine compounds as kinase inhibitors
WO2011005119A1 (en) * 2009-07-07 2011-01-13 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
CN102264721A (zh) * 2008-11-10 2011-11-30 沃泰克斯药物股份有限公司 用作atr激酶抑制剂的化合物
WO2012044641A1 (en) * 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
CN109651341A (zh) * 2017-10-11 2019-04-19 上海医药工业研究院 二吗啉氰基嘧(吡)啶类衍生物及作为抗肿瘤药物应用
CN110467610A (zh) * 2018-05-10 2019-11-19 四川科伦博泰生物医药股份有限公司 一种取代嘧啶化合物、其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
CA3074719A1 (en) * 2017-09-08 2019-03-14 Bluevalley Pharmaceutical Llc Substituted pyrrolopyridines as atr inhibitors
LT3753937T (lt) * 2018-02-07 2024-02-26 Wuxi Biocity Biopharmaceutics Co., Ltd. Atr inhibitorius ir jo taikymas
JP7485701B2 (ja) * 2019-06-06 2024-05-16 北京泰徳製薬股▲フン▼有限公司 Ａｔｒキナーゼ阻害剤としての２，４，６－三置換ピリミジン化合物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008032086A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab 2-benzimidazolyl-6-morpholino-4-phenylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2009093981A1 (en) * 2008-01-23 2009-07-30 S Bio Pte Ltd Triazine compounds as kinase inhibitors
CN102264721A (zh) * 2008-11-10 2011-11-30 沃泰克斯药物股份有限公司 用作atr激酶抑制剂的化合物
WO2011005119A1 (en) * 2009-07-07 2011-01-13 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
WO2012044641A1 (en) * 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
CN109651341A (zh) * 2017-10-11 2019-04-19 上海医药工业研究院 二吗啉氰基嘧(吡)啶类衍生物及作为抗肿瘤药物应用
CN110467610A (zh) * 2018-05-10 2019-11-19 四川科伦博泰生物医药股份有限公司 一种取代嘧啶化合物、其制备方法和用途

Also Published As

Publication number Publication date
JP2023528289A (ja) 2023-07-04
WO2021233376A1 (zh) 2021-11-25
KR20230012584A (ko) 2023-01-26
US20230212160A1 (en) 2023-07-06
EP4155307A4 (en) 2023-09-13
EP4155307A1 (en) 2023-03-29

Similar Documents

Publication Publication Date Title
CN115151532B (zh) 喹喔啉二酮衍生物作为kras g12c突变蛋白的不可逆抑制剂
CN114829364B (zh) 抑制并诱导降解egfr激酶的化合物
CN112047938B (zh) 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
CN109851638B (zh) 取代的二氨基嘧啶化合物
US11254696B2 (en) Dianilinopyrimidine compound for inhibiting kinase activity
CN116478136A (zh) 2-哌啶基或2-吡唑基取代的嘧啶化合物作为egfr抑制剂
EP3715350B1 (en) Arylphosphine oxides for inhibiting kinase activity
CN109923115B (zh) 咪唑并[1’,2’:1,6]吡啶并[2,3-d]嘧啶类化合物作为蛋白激酶抑制剂
CN115551860A (zh) 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
CN113929688B (zh) 作为atr激酶抑制剂的吡唑并嘧啶化合物
CN116462685A (zh) 杂环化合物、包含其的药物组合物及其抗肿瘤应用
CN114874189B (zh) 取代的杂芳基衍生物及其组合物及用途
CN117800922A (zh) Sos1抑制剂
CN117003757A (zh) 取代的双环杂芳基化合物作为usp1抑制剂
CN112552348A (zh) 含硒化合物及其制备和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40078576

Country of ref document: HK